Literature DB >> 17659994

TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.

Narendra Thapa1, Byung-Heon Lee, In-San Kim.   

Abstract

TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with TGF-beta. Its precise function remains obscure but a number of studies have demonstrated it to be an intriguingly versatile molecule role in a wide range of physiological and pathological conditions. To date, the most extensively studied and reported action of TGFBIp/betaig-h3 protein is in corneal dystrophy and several excellent reviews are available on this. Work from various laboratories on this molecule has compiled a tremendous amount of information over the past decade and a half. Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659994     DOI: 10.1016/j.biocel.2007.06.004

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  83 in total

Review 1.  The multiple facets of periostin in bone metabolism.

Authors:  B Merle; P Garnero
Journal:  Osteoporos Int       Date:  2012-02-07       Impact factor: 4.507

Review 2.  Calcium signaling in the liver.

Authors:  Maria Jimena Amaya; Michael H Nathanson
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity via alphavbeta3 and alpha5beta1 integrins.

Authors:  Ju-Ock Nam; Mi-Yeon Jung; Narendra Thapa; Byung-Heon Lee; Rang-Woon Park; In-San Kim
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

4.  Comparative transcriptional analysis of three human ligaments with distinct biomechanical properties.

Authors:  Carlos I Lorda-Diez; Ana Canga-Villegas; Luis Cerezal; Santiago Plaza; Juan M Hurlé; Juan A García-Porrero; Juan A Montero
Journal:  J Anat       Date:  2013-10-16       Impact factor: 2.610

5.  Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays.

Authors:  Wenbo Zhi; Ashok Sharma; Sharad Purohit; Eric Miller; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Leigh Steed; Diane Hopkins; Jin-Xiong She
Journal:  Mol Cell Proteomics       Date:  2011-09-06       Impact factor: 5.911

Review 6.  Macrophage phenotypes during tissue repair.

Authors:  Margaret L Novak; Timothy J Koh
Journal:  J Leukoc Biol       Date:  2013-03-15       Impact factor: 4.962

7.  TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells.

Authors:  Gengyun Wen; Michael A Partridge; Bingyan Li; Mei Hong; Wupeng Liao; Simon K Cheng; Yongliang Zhao; Gloria M Calaf; Tian Liu; Jun Zhou; Zengli Zhang; Tom K Hei
Journal:  Cancer Lett       Date:  2011-05-10       Impact factor: 8.679

8.  Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

Authors:  Gengyun Wen; Mei Hong; Bingyan Li; Wupeng Liao; Simon K Cheng; Burong Hu; Gloria M Calaf; Ping Lu; Michael A Partridge; Jian Tong; Tom K Hei
Journal:  Int J Oncol       Date:  2011-06-23       Impact factor: 5.650

9.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

10.  Periostin as a heterofunctional regulator of cardiac development and disease.

Authors:  Simon J Conway; Jeffery D Molkentin
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.